{"analyses":[{"ciLowerLimit":"-1.94","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"11.70","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Difference in event-free rates","paramValue":"4.88"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"44.47","upperLimit":"54.10","value":"49.28"},{"groupId":"OG001","lowerLimit":"39.57","upperLimit":"49.24","value":"44.40"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"442"},{"groupId":"OG001","value":"440"}],"units":"Participants"}],"description":"DFS rate was defined as percentage of participants who were disease-free at Year 5. DFS rate was analyzed in participants with disease stage II-IIIA. The DFS rate was estimated by the Kaplan-Meier methodology for each treatment arm. Percentages have been rounded off to the nearest decimal.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants who did not experience disease recurrence after chemotherapy in enrollment phase received 1200 milligrams (mg) of atezolizumab intravenously (IV) every 3 weeks (Q3W) for sixteen 21-day cycles in the randomization phase.","id":"OG000","title":"Atezolizumab"},{"description":"Participants who did not experience disease recurrence after chemotherapy in enrollment phase received no treatment in the randomization phase BSC arm.","id":"OG001","title":"Best Supportive Care (BSC)"}],"paramType":"NUMBER","populationDescription":"Stage II-IIIA population was defined as all randomized participants with extent of disease as either Stage II or Stage III, and is a subset of the ITT population. Randomized ITT population was defined as all randomized participants with resected Stage IB (tumors ≥ 4 cm)-IIIA NSCLC whether or not the participant received the assigned treatment.","reportingStatus":"POSTED","timeFrame":"Year 5","title":"Disease-free Rate at Year 5 in All Randomized Stage II-IIIA Population","type":"SECONDARY","unitOfMeasure":"percentage of participants"}